title: Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?
abstract: The global roll-out of Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) has changed the diagnostic landscape of tuberculosis (TB). More than 16 million tests have been performed in 122 countries since 2011, and detection of multidrug-resistant TB has increased three- to eight-fold compared to conventional testing. The roll-out has galvanised stakeholders, from donors to civil society, and paved the way for universal drug susceptibility testing. It has attracted new product developers to TB, resulting in a robust molecular diagnostics pipeline. However, the roll-out has also highlighted gaps that have constrained scale-up and limited impact on patient outcomes. The roll-out has been hampered by high costs for under-funded programmes, unavailability of a complete solution package (notably comprehensive training, quality assurance, implementation plans, inadequate service and maintenance support) and lack of impact assessment. Insufficient focus has been afforded to effective linkage to care of diagnosed patients, and clinical impact has been blunted by weak health systems. In many countries the private sector plays a dominant role in TB control, yet this sector has limited access to subsidised pricing. In light of these lessons, we advocate for a comprehensive diagnostics implementation approach, including increased engagement of in-country stakeholders for product launch and roll-out, broader systems strengthening in preparation for new technologies, as well as quality impact data from programmatic settings.
authors.affiliation: FIND, Cape Town, South Africa heidi.albert@finddx.org.
authors.forename: Heidi
authors.initials: H
authors.lastname: Albert
authors.affiliation: Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
authors.forename: Ruvandhi R
authors.identifier: 0000-0002-3544-5021
authors.initials: RR
authors.lastname: Nathavitharana
authors.affiliation: FIND, Geneva, Switzerland.
authors.forename: Chris
authors.initials: C
authors.lastname: Isaacs
authors.affiliation: Dept of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
authors.forename: Madhukar
authors.initials: M
authors.lastname: Pai
authors.affiliation: Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA FIND, Geneva, Switzerland.
authors.forename: Claudia M
authors.initials: CM
authors.lastname: Denkinger
authors.affiliation: FIND, Geneva, Switzerland.
authors.forename: Catharina C
authors.initials: CC
authors.lastname: Boehme
mesh_terms: D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D003140:Communicable Disease Control; D024881:Drug Resistance, Bacterial; D014943:Global Health; D017048:Health Care Costs; D006291:Health Policy; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D000067716:Point-of-Care Testing; D017149:Private Sector; D011785:Quality Assurance, Health Care; D012293:Rifampin / Q000627:therapeutic use; D013183:Sputum / Q000187:drug effects; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control
chemical_list: D000904:Antibiotics, Antitubercular; D012293:Rifampin